Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 30 Small Cell Lung Carcinoma 13 Recurrence 3 Melanoma 3 Lung Neoplasms 3 Advanced Lung Cancer 3 NSCLC 2 Lymphoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Treatment-naive Advanced Non-small Cell Lung Cancer 1 Thoracic Neoplasms 1 Stage IB-IIIB NSCLC 1 Small Cell Lung Cancer Limited Stage 1 Sarcoma 1 SCLC, Extensive Stage 1 Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1 Ovarian Neoplasms 1 Non-small Lung Cancer 1 Non Squamous Non Small Cell Lung Cancer 1 Non Small Cell Lung Cancer Recurrent 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mesothelioma, Malignant 1 Lung Diseases 1 Local Advanced Non-small Cell Lung Cancer 1 Liver Neoplasms 1 Kidney Neoplasms 1

Interventions

pembrolizumab 2 toripalimab 1 sintilimab 1 pemigatinib 1 osimertinib 1 durvalumab 1 Vinorelbine 1 Platinum Compounds 1 Nivolumab 1 Ipilimumab 1 Drug Therapy 1 AZD 6244 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non Small Cell Lung Cancer × toripalimab × Thoracic × Clear all

NCT04144608 2024-08-09

TOGATHER

Hunan Province Tumor Hospital

Phase 2 Completed

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡